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Abstract: In autism spectrum disorders (ASD) many individuals have co-morbid immune
dysregulation that can lead to inflammation in the brain and periphery. The novel cytokine
interleukin (IL)-35 has described anti-inflammatory properties; however, the plasma levels of IL-35
in children with ASD have never been investigated. The plasma levels of IL-35 were measured by
an enzyme-linked immunosorbent assay in 30 children with ASD and 39 typically developing (TD)
controls. In the current study, we found that plasma IL-35 levels were significantly decreased in
children with ASD compared with TD children. Furthermore, lower IL-35 levels were associated with
worse behaviors as assessed using the aberrant behavior checklist. These findings are in line with
other observations of decreased regulatory cytokines such as transforming growth factor beta and
IL-10 in ASD, and associations with severity of behaviors. In conclusion, regulating the expression of
IL-35 may provide a new possible target for the treatment of immune issues in ASD to address an
imbalance between pro- and anti-inflammatory signals that alter the behavioral phenotype.
Keywords: autism spectrum disorders; cytokines; immune regulation; interleukin; IL-35;
anti-inflammatory
1. Introduction
The prevalence of autism spectrum disorders (ASD) has seen dramatic rises over the last 20
years and is now estimated to affect nearly 2% of young children in the United States [1]. Defined
by behavioral criteria based on impairments in social interactions, communication, and repetitive
behaviors, the etiology of ASD is still largely unknown but likely involves complex environmental
and genetic factors [2–4]. Aberrant immune responses have been postulated to be involved in ASD
pathophysiology, either as a cause of autism-like symptoms (as highlighted in animal models and
human studies that involve maternal immune activation), or through ongoing immune activation
which can lead to more impaired behaviors [5–9]. Increased allergies, asthma and autoimmunity have
also been shown in ASD [10–16]. In many studies, the focus has been on the activation or increase
of pro-inflammatory elements such as cytokines, T cells, innate immune cells, and auto-antibodies
(reviewed in Hughes [2]). While compelling evidence highlights that multiple effectors are activated in
ASD, no clear consensus has been reached as to a specific response mechanism with many different
arms of the immune response being activated [17]. In fact, recent data suggests that an underlying
mechanism may be the lack of immune regulation.
Immune regulation is mediated by the combination of regulatory immune cells and the release
of immune suppressive or anti-inflammatory cytokines. In ASD, several studies have shown that
regulatory cytokines such as transforming growth factor beta-1 (TGFβ1) or interleukin (IL)-10 are
decreased [9,18–25]). Moreover, decreases in regulatory T cells (Tregs) have also been described [26,27].
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IL-35 is a novel cytokine with recently described immune suppressive activities. It is a member of
the IL-12 family of cytokines composed of an alpha chain (p35) and a beta chain that is a L-27 subunit
Epstein–Barr virus-induced gene 3 (EBI3). IL-35 is released by regulatory CD4+ and CD8+ T (Treg)
cells, dendritic cells, and regulatory B cells. The main effector mechanism of IL-35 appears in the
inhibition of T helper type 17 (TH17) and proliferation of Treg. Decreased IL-35 has been shown in
auto-inflammatory conditions, such as multiple sclerosis, inflammatory bowel disease, systemic lupus
erythematosus, rheumatoid arthritis, and psoriasis [28,29].
We have previously hypothesized that there is a dysregulation in the balance between TH17 and
Treg cells in ASD [9], thus potentially making IL-35 a key player in this dynamic. In this pilot study, we
sought to examine plasma levels of IL-35 in children with ASD and age-, and geographically matched
control samples from typically developing children. In addition, we examined whether there were
associations between IL-35 levels and subscale scores on the Aberrant Behavior Checklist (ABC).
2. Methods
2.1. Subjects
The recruitment of study participants was through the UC Davis MIND Institute. Each participant
was previously enrolled in the Childhood Autism Risk from Genetics and Environment (CHARGE)
study [30]. A total of 69 participants comprised this study, composed of 30 children with ASD (median:
7.7 years of age; interquartile range (IQR): 5.3–10.3 years; 26 males, 4 females) and 39 who were
typically developing (TD) (7 years of age; 5.6–8.4 years; 36 males, 3 females). The participants’ age
ranged from 3 to 12 years old. The autism spectrum disorder diagnosis was verified by trained
clinicians at the UC Davis MIND Institute and the diagnoses occurred before 2013 and were, therefore,
based on DSM IV following the Autism Diagnostic Observation Schedule (ADOS) and the Autism
Diagnostic Interview-Revised (ADI-R). The diagnosis was determined between the age of 2–5 when the
participants were originally enrolled into the CHARGE study. Each participant who was placed in the
control group was prescreened with the Social Communication Questionnaire (SCQ), the Mullen Scales
of Early Learning (MSEL), and the Vineland Adaptive Behavior Score (VABS) in order to eliminate
behavioral and developmental characteristics of ASD. TD participants were required to score inside
the typical range, specifically below 15, on the SCQ and above 70 on the MSEL and VABS. The subjects
for this study were recruited at random from the CHARGE study database, care was taken to ensure
typically developing subjects were frequency matched to ASD subjects based on birth location, age, and
sex. All subjects were evaluated using the Aberrant Behavior Checklist (ABC) to evaluate impairments
within the domains of lethargy, stereotypic behavior, social withdrawal, irritability, hyperactivity, and
inappropriate speech when they were enrolled in the current study. Medications that were used at
the time of enrollment were recorded and they included Albuterol, Claritin, Cimetidine, Clonidine,
Flonase, Flovent, Fluticasone, Guanfacine, Ibuprofen, Qvar, Risperidone, Singulair, Strattera, Tenex,
Triaminic, Tylenol, Zantac, and Zyrtec. Excluding the 12 subjects who were taking one or more of the
listed medications did not significantly alter the results so they were included in the final analysis
presented here.
Participants were excluded if they met any of these exclusion criteria: evidence of fever, genetic
disorders (such as Fragile X syndrome or Tuberous Sclerosis Complex), seizure disorder, pancreatic or
liver disease, cystic fibrosis, or other chronic infections.
The approval for this study was given by institutional review boards for the State of California
and the University of California, Davis. In accordance with UC Davis IRB protocol, informed consent
was obtained from a legal guardian for all study participants prior to data collection.
2.2. Blood Collection and Cytokine Analysis
Peripheral blood was obtained from each participant in acid-citrate dextrose Vacutainers (BD
Biosciences; San Jose, CA, USA) and processed within 8 hours of being drawn. Vacutainers containing
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blood were centrifuged at a speed of 2100 rpm for 10 minutes, plasma was collected, aliquoted, and
stored at −80◦ until analysis.
The quantification of IL-35 was completed via a multiplexing bead immunoassay (Millipore,
Billerica, MA, USA) following the manufacturer’s protocol. Briefly, overnight incubation of 25 µL
of 1:2 diluted plasma with antibody coupled fluorescent beads, was followed by a washing step
before further incubation with biotinylated detection antibodies for 1 hour preceding the addition
and incubation of streptavidin–phycoerythrin for 30 min before one final wash. Following the last
wash the beads were analyzed on the flow-based Luminex™ 100 suspension array system (Bio-Plex
200; Bio-Rad Laboratories, Inc., Hercules, CA, USA). To determine unknown sample concentrations, a
standard curve was prepared using reference IL-35 provided by the manufacturer in the kit and ran in
the same assay with the samples. The kit listed the minimum detectable amount of IL-35 as 0.3 ng/mL.
Samples with concentrations that were determined to be lower than the limit of detection were given a
proxy value of half the limit of detection for statistical comparisons.
2.3. Statistical Analysis
Performing a Shapiro–Wilk normality test on the IL-35 data revealed non-parametric distribution
of the data, in which standard transformation processes (i.e., log transformation, square-root
transformation) could not normalize, therefore, the data is presented as median values with
interquartile ranges in parentheses. A Mann–Whitney non-parametric U-test was used to compare IL-35
concentrations across study groups. Findings were considered significant if adjusted p values were less
than 0.05. Outliers were eliminated using ROUT. Associations between behavioral data (ABC subscales)
and plasma IL-35 concentrations were analyzed utilizing the non-parametric, Spearman’s correlation.
3. Results
Plasma from children with ASD contained lower concentrations of the regulatory cytokine IL-35
(median: 3.30 ng/mL; IQR: 0.35–8.51 ng/mL) compared to typically developing children (7.47 ng/mL;
4.71–10.02 ng/mL) p = 0.023 (Figure 1). When analyzing for associations with behavioral data using
ABC assessments, we found that plasma IL-35 concentrations were inversely correlated with lethargy
(r: −0.388; p = 0.002), hyperactivity (r: −0.368; p = 0.003), and inappropriate speech (r: −0.250; p = 0.046)
(Figure 2).
Figure 1. Comparison of plasma IL-35 levels (ng/mL) in children with autism (n = 30) and typically
developing controls (n = 39). Data is depicted as box and whisker graphs, comparing medians. * denotes
p-value > 0.05.
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Figure 2. Plasma IL-35 concentration correlated behavioral data from the ABC subscales, lethargy (a),
hyperactivity/noncompliance (b), and inappropriate speech (c). Data presented as scatter plots with
linear regression lines and 95% confidence lines.
4. Discussion
To the best of our knowledge, this is the first study to assess the plasma IL-35 concentration in
ASD. Our results demonstrated that there are decreased levels of plasma IL-35 in children with ASD.
Moreover, we found associations between IL-35 levels and more impairment in behavior. It is currently
unknown whether IL-35 can affect neuronal function, neurodevelopment and consequently directly
alter behaviors, and this data should be treated with caution. However, of note, multiple studies have
shown that impairments in core ASD features and associated behaviors, are strongly correlated with
altered immune profiles [2–4,31]. A decrease in immune regulation via IL-35 could lead to a tip in the
balance towards enhanced immune activation that could alter neurodevelopment. Further validation
of the link between observed behavioral severity and IL-35 its receptors/signaling is warranted in ASD.
Decreased levels of anti-inflammatory immunosuppressive cytokines, such as TGFβ1 and IL-10
have previously been shown in ASD. We and others have shown that plasma levels of TGFβ1 were
reduced in ASD compared to TD controls and children with other developmental disabilities [18,22,32].
Lower TGFβ1 levels in children with ASD were associated with fewer social interactions, worse
adaptive behaviors, hyperactivity, irritability, and stereotypies [18]. Furthermore, in the analysis of 414
ASD and 820 TD newborn blood spots, TGFβ1 levels were significantly decreased in ASD [33]. Adding
further support to decreased regulation playing a role in the pathophysiology of ASD, differentially
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expressed microRNAs (miRNAs) that control TGFβ1 pathways were found in ASD [34–36]. In
cell stimulation assays, studies showed that the production of IL-10 by CD4+ T cells was reduced
in ASD [20,21,37,38]. Peripheral blood mononuclear cells (PBMC) also produce less TGFβ1 upon
stimulation [9]. These data suggest there is a lack of immune regulation due to decreased production
of one or more regulatory cytokine in children with ASD and is associated with worse behavior.
Regulatory T cells are also decreased in ASD. CD4+CD25++ cells are considered enriched for a
population of cells with suppressive activity. We assessed CD4+CD25++ T cells by flow cytometry in
65 children with a confirmed diagnosis of ASD and 73 TD controls and found an ~30% decrease in the
frequency of CD4+CD25++ cells in ASD [26]. The circulating frequency of CD4+CD25+ Tregs in blood
was also examined in 30 ASD children and compared to 30 TD controls in Egypt [27]. The authors
found that ASD children typically had 75% fewer CD4+CD25+ Tregs compared with controls and
that those with severe ASD had approximately 90% fewer CD4+CD25+ Tregs. Two older studies also
describe deficiencies in lymphocyte populations that may possess regulatory properties in ASD [39,40].
IL-35 is a recently described cytokine with inhibitory properties, produced primarily by regulatory T
and B cells and is required for Treg-mediated immunosuppression. This may suggest that decreases in
Tregs numbers or defects in Tregs function may drive lower IL-35, TGFβ1 and IL-10 levels.
Exciting and intriguing data suggest that targeting the immune response by exerting greater
control/regulation/suppression can be a beneficial therapy in ASD (reviewed in [41]), showing
improvements of core-ASD and associated behaviors; including, social interactions, language,
vocalization, stereotypic behavior, irritability, and emotional regulation. However, often these
studies are limited to small trials that need careful replication. Cord blood cell transplantation was rich
in Tregs and induced significant behavioral improvements in ASD [42,43]; although the specific cell type
responsible for these positive outcomes has not yet been identified. Enhancing the power of Tregs to
control responses can lead to better regulation. A more comprehensive understanding of the complex
mechanisms of immune regulation in ASD will advance the development of targeted therapies.
5. Conclusions
To summarize, the results described here are in agreement with prior studies and suggest that
regulatory anti-inflammatory mediators are decreased in ASD and could contribute to pathophysiology
and behavioral symptoms. Furthermore, future studies, such as longitudinal measurements of the
current subjects, could further elucidate the putative role of IL-35 concentrations as biological signatures
of the progression and development of ASD. Additional studies will be necessary to better understand
the relationship of IL-35 in ASD development and the role of this cytokine and its cognate receptors
play in the brain.
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